2-Aethyl-4.5-pentamethylen-thiazol | 117876-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Aethyl-4.5-pentamethylen-thiazol
• 英文别名: 2-ethyl-5,6,7,8-tetrahydro-4H-cycloheptathiazole；2-ethyl-5,6,7,8-tetrahydro-4H-cyclohepta[d][1,3]thiazole
• CAS: 117876-57-0
• 化学式: C₁₀H₁₅NS
• 分子量: 181.302
• InChiKey: NCVCNRKGGLZJJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-ethyl-4,5,6,7,8,8a-hexahydro-2H-cycloheptathiazole 在 sulfur 作用下， 反应 2.0h， 生成 2-Aethyl-4.5-pentamethylen-thiazol
  参考文献：
  名称：

  Asinger,F. et al., Justus Liebigs Annalen der Chemie, 1960, vol. 634, p. 144 - 163

  摘要：

  DOI：

文献信息

• BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS
  申请人：BISTOL-MYERS SQUIBB COMPANY

  公开号：US20190292176A1

  公开（公告）日：2019-09-26

  Disclosed are compounds of Formula (I) to (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII); or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a bicyclic heteroaryl group substituted with zero to 3 R 3a ; and R 1 , R 2 , R 3a , R 4 , and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
• SMALL MOLECULE MODULATORS OF MHC-I
  申请人：RetroVirox, Inc.

  公开号：US20220411419A1

  公开（公告）日：2022-12-29

  The invention disclosed herein are embodiments of compounds capable of treating a viral infection. For example, the compounds are capable of inhibiting viral downmodulation of major histocompatibility complex I (MHC-I), such as by acting as immunomodulators of the immune system to treat, cure or eradicate a viral infection (e.g., HIV infection). More particularly, the present disclosure relates to the use of a heteroaryl compound or salts or analogs thereof, in the treatment of patients infected with a virus. The disclosed compounds may be used alone or in combination with other pharmacologically active agents to treat, cure or eradicate the virus, particularly in patients with persistent, latent viral infection. In some embodiments, the disclosed compounds can be used alone or in combination with other pharmacologically active agents to promote reactivation of viral production in latent cells and eradication of such cells.